Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027

Verastem, Inc.

AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.
Phase 3 RAMP 301 trial fully accrued; topline PFS data expected mid-2027.
VS-7375 KRAS G12D inhibitor: cleared 900 mg QD dose no DLTs; FDA FTD in PDAC.
Pipeline milestones: RAMP 205 update 1H2026; VS-7375 monotherapy expansion cohorts 1H2026.
Extended cash runway into 1H2027 via Oberland debt refinancing and equity investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.